Gilead Sciences Inc (GILD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $208.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
Gilead Sciences Inc (GILD) Stock Forecast
Analysts expect Gilead Sciences (GILD) to earn -$0.98 per share in the fiscal year ending Dec 31, 2026, on revenue of $31.36B. Of 28 analysts, 22 rate the stock Buy or Strong Buy, 5 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 23 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 79% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 6 | 21.4% |
| Buy | 16 | 57.1% |
| Hold | 5 | 17.9% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 3.6% |
- Consensus
- Buy
- Total analysts
- 28
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 7.1%.
- Fiscal year ending Dec 31, 2026
- -$0.98
- EPS consensus, revenue $31.36B
- Fiscal year ending Dec 31, 2027
- $10.13
- EPS consensus, revenue $33.58B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.98 | -$1.20 to -$0.73 | 24 | $31.36B | $30.53B to $31.60B | 25 |
| Dec 31, 2027 | $10.13 | $8.91 to $12.41 | 27 | $33.58B | $32.21B to $34.76B | 25 |
Quarterly Estimates
The EPS consensus rises from $1.22 for the quarter ending Dec 31, 2026 to $2.14 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.22 | $0.90 to $2.28 | 23 | $8.51B | $8.09B to $8.96B | 20 |
| Mar 31, 2027 | $2.14 | $1.90 to $2.26 | 6 | $7.44B | $7.28B to $7.58B | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 17 upward and 30 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 23 |
| Fiscal year ending Dec 31, 2027 | 16 | 4 |
| Quarter ending Mar 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.98 | -$0.99 | -$0.40 | -$0.43 | -$0.43 | N/A |
| Fiscal year ending Dec 31, 2027 | $10.13 | $10.10 | $9.94 | $9.89 | $9.89 | +2.4% |
| Quarter ending Mar 31, 2027 | $2.14 | $2.17 | $2.31 | $2.30 | $2.30 | -7.1% |
Frequently Asked Questions About GILD
What is the GILD stock forecast?
Consensus analyst estimates put Gilead Sciences's EPS at -$0.98 for the fiscal year ending Dec 31, 2026, on revenue of $31.36B. The consensus rating from 28 analysts is Buy.
How do analysts rate GILD stock?
Of 28 analysts covering Gilead Sciences, 6 rate it Strong Buy, 16 Buy, 5 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GILD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.98, with estimates from -$1.20 to -$0.73 from 24 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $10.13, with estimates from $8.91 to $12.41 from 27 analysts.
What revenue do analysts expect from Gilead Sciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $31.36B, with estimates from $30.53B to $31.60B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $33.58B, with estimates from $32.21B to $34.76B.
How many analysts cover GILD?
28 analysts rate Gilead Sciences stock, and 24 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GILD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts